Investigating the prevalence of dyslipidemia in different obesity groups in the Fasa cohort ‎population

Document Type : Research Paper

Authors

1 Department of Anatomical Sciences, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran

2 Department of Tissue Engineering, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran

3 Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran

4 Vascular and endovascular surgery research center, Mashhad University of Medical Sciences, Mashhad, Iran

5 Metabolic syndrome research center, Mashhad University of Medical Sciences, Mashhad, Iran

6 Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran

10.22038/mjms.2025.80075.4621

Abstract

Introduction: Obesity and dyslipidemia are critical risk factors for cardiovascular diseases (CVD). ‎This study aims to assess the prevalence of dyslipidemia across various obesity categories in the adult ‎population of the Fasa cohort. ‎
Methodology: Utilizing a descriptive-analytical, cross-sectional design, the study sampled 10,118 ‎participants aged 35 to 70, categorized into eight groups based on BMI and metabolic syndrome status: ‎normal BMI, BMI 25-29.9, BMI 30-34.9, and BMI ≥35, each further divided by the presence or ‎absence of metabolic syndrome. Dyslipidemia prevalence was evaluated across these groups using chi-‎square tests and one-way ANOVA, while logistic regression analyzed the impact of each variable on ‎metabolic syndrome. Statistical significance was set at a 0.05 threshold, with SPSS software facilitating ‎data analysis. ‎
Results: The findings revealed dyslipidemia prevalence rates of 87.8% for BMI 25-29.9, 89.1% for ‎BMI 30-34.9, and 91.5% for BMI ≥35. Individuals with metabolic syndrome exhibited higher ‎dyslipidemia prevalence across all BMI groups compared to those without metabolic syndrome. ‎Additionally, the odds of having dyslipidemia in those with metabolic syndrome were 45.1% higher in ‎the BMI 25-29.9 group and 67.4% higher in the BMI 30-34.9 group than in healthy individuals. ‎
Discussion and conclusion: The high prevalence of dyslipidemia in this population underscores the ‎need for targeted policy interventions to mitigate the associated health risks and financial burdens.‎

Keywords

References

  1. Thongtang N, Sukmawan R, Llanes EJB, Lee Z-V. Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices. Preventive medicine reports. 2022;27:101819.
  2. Berman AN, Blankstein R. Optimizing dyslipidemia management for the prevention of cardiovascular disease: a focus on risk assessment and therapeutic options. Current cardiology reports. 2019;21:1-10.
  3. Lazarte J, Hegele RA. Dyslipidemia management in adults with diabetes. Canadian journal of diabetes. 2020;44(1):53-60.
  4. Bahiru E, Hsiao R, Phillipson D, Watson KE. Mechanisms and treatment of dyslipidemia in diabetes. Current cardiology reports. 2021;23:1-6.
  5. Chen K-N, He L, Zhong L-M, Ran Y-Q, Liu Y. Meta-analysis of dyslipidemia management for the prevention of ischemic stroke recurrence in China. Frontiers in neurology. 2020;11:483570.
  6. Chang Y, Eom S, Kim M, Song T-J. Medical Management of Dyslipidemia for secondary stroke prevention: narrative review. Medicina. 2023;59(4):776.
  7. Arvanitis M, Lowenstein CJ. Dyslipidemia. Annals of internal medicine. 2023;176(6):ITC81-ITC96.
  8. Liu T, Zhao D, Qi Y. Global trends in the epidemiology and management of dyslipidemia. Journal of clinical medicine. 2022;11(21):6377.
  9. Hovsepian S, Kelishadi R, Djalalinia S, Farzadfar F, Naderimagham S, Qorbani M. Prevalence of dyslipidemia in Iranian children and adolescents: A systematic review. Journal of research in medical sciences. 2015;20(5):503-21.
  10. Darroudi S, Saberi‐Karimian M, Tayefi M, Arekhi S, Motamedzadeh Torghabeh A, Seyedzadeh Sani SMR, et al. Prevalence of combined and noncombined dyslipidemia in an Iranian population. Journal of clinical laboratory analysis. 2018;32(8):e22579.
  11. Tabrizi JS, Nikniaz L, Sadeghi-Bazargani H, Farahbakhsh M, Nikniaz Z, Farhangi MA, et al. Prevalence of dyslipidemia in urban and rural areas of the Northwest of Iran: the sociodemographic, dietary and psychological determinants. Iranian journal of public health. 2019;48(5):925.
  12. Khanali J, Ghasemi E, Rashidi M-M, Ahmadi N, Ghamari S-H, Azangou-Khyavy M, et al. Prevalence of plasma lipid abnormalities and associated risk factors among Iranian adults based on the findings from STEPs survey 2021. Scientific Reports. 2023;13(1):15499.
  13. Tabatabaei-Malazy O, Qorbani M, Samavat T, Sharifi F, Larijani B, Fakhrzadeh H. Prevalence of dyslipidemia in Iran: a systematic review and meta-analysis study. International journal of preventive medicine. 2014;5(4):373.
  14. Abiri B, Ahmadi AR, Amini S, Akbari M, Hosseinpanah F, Madinehzad SA, et al. Prevalence of overweight and obesity among Iranian population: a systematic review and meta-analysis. Journal of Health, Population and Nutrition. 2023;42(1):70.

15.Ashoorion V, Sarrafzadegan N, Shahidi S, Bagherikholenjani F. The Protocol for the Development of Iranian Clinical Practice Guideline on Dyslipidemia. ARYA Atherosclerosis Journal. 2023;19(6):27-35.

  1. Mirshekari M, Shirzad N, Hemmatabadi M, Namazi S. The approach of Iranian clinical pharmacists in the treatment of dyslipidemia based on international guidelines. Journal of Cardiovascular and Thoracic Research. 2023;15(1):30.
  2. Cheraghian B, Saki N, Sarvandian S, Hashemi SJ, Hosseini SA, Saki S, et al. Evaluation of dyslipidemia based on ATP ⅠⅠⅠ guideline in adults of southwest Iran: A population-based study. 2024.
  3. Toori MA, Kiani F, Sayehmiri F, Sayehmiri K, Mohsenzadeh Y, Ostovar R, et al. Prevalence of hypercholesterolemia, high LDL, and low HDL in Iran: a systematic review and meta-analysis. Iranian Journal of Medical Sciences. 2018;43(5):449.
  4. Nezafat AV, Tavakolifard N, Vaezi A. Adherence of general practitioners to the national hypertension guideline, Isfahan, Iran. International Journal of Preventive Medicine. 2020;11(1):130.
  5. Tóth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the united states: the national health and nutrition examination survey 2003–2006. Journal of clinical lipidology. 2012;6(4):325-30.
  6. Goff DC, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, et al. Dyslipidemia Prevalence, Treatment, and Control in the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2006;113(5).
  7. Halcox JP, Banegas JR, Roy C, Dallongeville J, De Backer G, Guallar E, et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovascular Disorders. 2017;17(1).
  8. Huang Y, Gao L, Xie X, Tan SC. Epidemiology of dyslipidemia in Chinese adults: meta-analysis of prevalence, awareness, treatment, and control. Population health metrics. 2014;12:1-9.
  9. Tabatabaei-Malazy O, Qorbani M, Samavat T, Sharifi F, Larijani B, Fakhrzadeh H. Prevalence of dyslipidemia in Iran: A systematic review and meta-analysis study. International Journal of Preventive Medicine2014.
  10. Latifi SM, Moradi L, Shahbazian H, Aleali AM. A study of the prevalence of dyslipidemia among the adult population of Ahvaz, Iran. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2016;10(4).
  11. Tabrizi JS, Nikniaz L, Sadeghi-Bazargani H, Farahbakhsh M, Nikniaz Z, Abbasalizad Farhangi M, et al. Prevalence of dyslipidemia in urban and rural areas of the Northwest of Iran: The sociodemographic, dietary and psychological determinants. Iranian Journal of Public Health. 2019;48(5).
  12. Zhang L, Zhang WH, Zhang L, Wang PY. Prevalence of overweight/obesity and its associations with hypertension, diabetes, dyslipidemia, and metabolic syndrome: A survey in the suburban area of Beijing, 2007. Obesity Facts. 2011;4(4).
  13. Bayram F, Kocer D, Gundogan K, Kaya A, Demir O, Coskun R, et al. Prevalence of dyslipidemia and associated risk factors in Turkish adults. Journal of Clinical Lipidology. 2014;8(2).
  14. Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine. 2008;34(1-3).
  15. Blaton VH, Korita I, Bulo A. How is metabolic syndrome related to dyslipidemia? Biochemia Medica2008.
  16. Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS. Association of Hypertension, Diabetes, Dyslipidemia, and Metabolic Syndrome with Obesity: Findings from the National Health and Nutrition Examination Survey, 1999 to 2004. Journal of the American College of Surgeons. 2008;207(6).
  17. Sangrós FJ, Torrecilla J, Giráldez-García C, Carrillo L, Mancera J, Mur T, et al. Association of General and Abdominal Obesity With Hypertension, Dyslipidemia and Prediabetes in the PREDAPS Study. Revista Española de Cardiología (English Edition). 2018;71(3).
  18. Zhu J, Zhang Y, Wu Y, Xiang Y, Tong X, Yu Y, et al. Obesity and Dyslipidemia in Chinese Adults: A Cross-Sectional Study in Shanghai, China. Nutrients. 2022;14(11).
Medical Journal of Mashhad university of Medical Sciences
Volume 68, Issue 1
March and April 2025
Pages 46-68

Files

Share

How to cite

Statistics